Supplemental material
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 22, 2022 - Issue 8
Original Research
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
Diana Mendesa Pfizer Ltd, Tadworth, UK
https://orcid.org/0000-0002-1672-4906View further author information
https://orcid.org/0000-0002-1672-4906View further author information, Ahuva Averinb Policy Analysis Inc. (PAI), Chestnut Hill, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-4490-7021View further author information
https://orcid.org/0000-0002-4490-7021View further author information, , Reiko Satoc Pfizer Inc, Collegeville, PA, USAhttps://orcid.org/0000-0003-2785-7103View further author information
https://orcid.org/0000-0003-2785-7103View further author information, Andrew Vysea Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0002-0339-7491View further author information
https://orcid.org/0000-0002-0339-7491View further author information, James Camplinga Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0002-6886-8565View further author information
https://orcid.org/0000-0002-6886-8565View further author information, Derek Weyckerb Policy Analysis Inc. (PAI), Chestnut Hill, MA, USAhttps://orcid.org/0000-0002-5405-2215View further author information
https://orcid.org/0000-0002-5405-2215View further author information, Mary Slackd School of Medicine & Dentistry, Griffith University, Gold Coast Campus, 4222, Australiahttps://orcid.org/0000-0001-5119-4085View further author information
https://orcid.org/0000-0001-5119-4085View further author information, Gillian Ellsburya Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0002-6855-4080View further author information
https://orcid.org/0000-0002-6855-4080View further author information & Tendai Mugwagwaa Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0001-7515-8548View further author information
https://orcid.org/0000-0001-7515-8548View further author information show all